AX-2026-041469
Humanin (HNG) · 10 mg declared · ChinaPeptides Co., Ltd. (QYAOBIO) · lot QYB-2512-A5720
- Report ID
- AX-2026-041469
- Compound
- Humanin (HNG)
- Compound class
- Metabolic and mitochondrial peptides
- Supplier
- QYB — ChinaPeptides Co., Ltd. (QYAOBIO)
- Batch / lot
- QYB-2512-A5720
- Declared label claim
- 10mg
- Laboratory
- Medutest
- Assay date
- 25 Mar 2026
- Submitted
- 29 Mar 2026
- Quarter
- 2026-Q1
- Submitter
- b.lundgren
- Sample provenance
- Supplier-supplied
Results
Measured against the index acceptance specification for the metabolic and mitochondrial peptides class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.
| Parameter | Method | Result | Unit | Index spec | |
|---|---|---|---|---|---|
| Purity | RP-HPLC, 25 min gradient, 214 nm | 99.64 | % area | ≥ 97.5 | PASS |
| Total impurities | RP-HPLC, sum of reported peaks | 0.36 | % area | ≤ 2.5 | PASS |
| Largest single impurity | RP-HPLC — wild-type humanin (Ser14, −42 Da) | 0.17 | % area | ≤ 1.00 | PASS |
| Identity — theoretical monoisotopic mass | calculated from molecular formula | 2685.3153 | Da | — | NOT TESTED |
| Identity — observed monoisotopic mass | LC-MS, unit resolution (single quadrupole) | 2685.2503 | Da | — | NOT TESTED |
| Mass accuracy | observed vs theoretical | -24.2 | ppm | ± 15 | FAIL |
| Total peptide content | by difference from the gravimetric mass balance | 88.42 | %w/w | — | NOT TESTED |
| Target-compound content | total peptide content × purity | 88.10 | %w/w | — | NOT TESTED |
| Gross fill (as weighed) | five-place balance, under nitrogen | 11.03 | mg | 10 mg declared | NOT TESTED |
| Recovered target peptide | gross fill × target content | 9.717 | mg | 10 mg claim | NOT TESTED |
| Recovery against label claim | recovered ÷ claim | 97.2 | % | 90.0 – 110.0 | PASS |
| Water content | Karl Fischer, coulometric, duplicate | 4.70 | % | ≤ 9.0 | PASS |
| Counter-ion (acetate) | anion-exchange ion chromatography | 5.93 | % | ≤ 12.0 | PASS |
| Residual solvent + inorganic residue | estimated — see /methods/residual-solvents-q3c/ | 0.95 | % | — | NOT TESTED |
| Endotoxin | not ordered on this submission | not determined | — | ≤ 5.0 | NOT TESTED |
| Sterility | not ordered on this submission | not determined | — | no growth | NOT TESTED |
| Appearance | visual, diffuse light, black and white background | White powder, no defined cake (melt-back) | — | white to off-white intact cake | FAIL |
| Reconstitution clarity | reconstituted per submitter procedure | Clear, colourless, no visible particulates | — | clear, no visible particulates | PASS |
| pH (reconstituted, 1 mg/mL) | potentiometric, two-point calibration | 5.45 | — | 2.5 – 8.0 | PASS |
| Retention time (observed) | RP-HPLC, 25 min gradient | 10.16 | min | 10.28 ± 0.30 (normalised) | PASS |
| Peak asymmetry (10 % height) | Ph. Eur. 2.2.46 | 1.03 | — | 0.80 – 1.50 | PASS |
| Plate count, main peak | N = 5.54 (t/w½)² | 47,577 | — | ≥ 20,000 | PASS |
| Resolution to nearest impurity | vs wild-type humanin (Ser14, −42 Da) | 0.65 | — | no index criterion | REPORTED |
Chromatogram and peak integration
The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.
| # | Peak | RT | Area (µV·s) | % area | Δ mass (Da) |
|---|---|---|---|---|---|
| 1 | Humanin (HNG) — main peak | 10.16 | 4,842,813 | 99.64 | — |
| 2 | wild-type humanin (Ser14, −42 Da) | 10.04 | 8,263 | 0.17 | -42.011 |
| 3 | truncated (1-20) | 9.04 | 3,888 | 0.08 | -472.245 |
| 4 | Met sulfoxide (+16 Da) | 9.81 | 3,402 | 0.07 | +15.995 |
| 5 | deamidated (+1 Da) | 9.93 | 1,944 | 0.04 | +0.984 |
| Closure check — purity + Σ impurities | 100.00 | CLOSES | |||
Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.
Mass spectrum and identity
Theoretical monoisotopic mass 2685.3153 Da, computed from C119H182N30O32S. All ppm figures on this site are against monoisotopic values — see why that matters.
| Charge | Theoretical m/z | Observed m/z | Δ m/z | Rel. abundance (%) |
|---|---|---|---|---|
| 5+ | 538.0703 | 538.0573 | -0.0130 | 8.5 |
| 4+ | 672.3361 | 672.3199 | -0.0162 | 56.3 |
| 3+ | 896.1124 | 896.0907 | -0.0217 | 100.0 |
| 2+ | 1343.6649 | 1343.6324 | -0.0325 | 57.4 |
Gravimetric mass balance
Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.
| Component | Determination | %w/w of cake |
|---|---|---|
| Water | Karl Fischer | 4.70 |
| Counter-ion (acetate) | ion chromatography | 5.93 |
| Residual solvent + inorganic residue | estimated | 0.95 |
| Total peptide content | by difference | 88.42 |
| Total | 100.00 CLOSES | |
Supplier certificate, as declared
The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.
| Figure | Supplier COA | This report | Index note |
|---|---|---|---|
| Purity (% area) | 99.33 | 99.64 | divergence -0.14 pp vs batch median |
| Total impurities (% area) | 0.67 | 0.36 | |
| Largest single impurity (% area) | 0.40 | 0.17 | |
| Water (%) | not stated | 4.70 | |
| Counter-ion (%) | 4.5 | 5.93 | |
| Peptide content (%w/w) | 91.4 | 88.42 | |
| Endotoxin (EU/mg) | 0.24 | not determined | |
| Method stated on certificate | YES | — | column, gradient and wavelength given |
Provenance and caveats
Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.
- Sample provenance
- Supplier-supplied
- Evidentiary weight
- Weaker evidence. Read with the caveat below.
- Chain of custody
- Supplier despatch → laboratory direct (courier, cold pack, 9 d) → assay. Submitter did not handle the vial.
- Assay date
- 25 Mar 2026
- Submitted to the index
- 29 Mar 2026
- Laboratory
- Medutest, Ljubljana, Slovenia
- Method basis
- 25 min gradient · unit-resolution MS
- Verification status
- IDENTITY CONSISTENT
Annotations
No annotations on this record. Annotations are short signed technical comments from index contributors; see how to contribute.
Related records
Same batch — lot QYB-2512-A5720 n=3
| Report | Lot | Lab | Quarter | Purity % | Water % | Recovery % | Provenance | Flags | Result |
|---|---|---|---|---|---|---|---|---|---|
| AX-2026-041470 | QYB-2512-A5720 | Kestrel | 2026-Q1 | 99.14 | 5.04 | 93.4 | Supplier-supplied | 2 | FAIL |
| AX-2026-041471 | QYB-2512-A5720 | Nordanalyt | 2026-Q1 | 99.47 | 4.06 | 97.9 | Supplier-supplied | 1 | MARGINAL |
Cross-sections
| Report | Supplier | Lot | Lab | Quarter | Purity % | Water % | Recovery % | Provenance | Flags | Result |
|---|---|---|---|---|---|---|---|---|---|---|
| AX-2026-041973 | TFC | TFC-2605-U5564 | Janoshik | 2026-Q3 | 99.62 | 7.03 | — | Supplier-supplied | 2 | FAIL |
| AX-2026-041980 | TFC | TFC-2605-U5564 | Janoshik | 2026-Q3 | 99.90 | 7.01 | 88.6 | Supplier-supplied | 2 | MARGINAL |
| AX-2026-041979 | TFC | TFC-2605-U5564 | Nordanalyt | 2026-Q3 | 99.73 | 6.64 | — | Supplier-supplied | 1 | MARGINAL |
| AX-2026-041981 | TFC | TFC-2605-U5564 | Medutest | 2026-Q3 | 99.87 | 6.84 | — | Supplier-supplied | 1 | MARGINAL |
| AX-2026-041975 | TFC | TFC-2605-U5564 | Nordanalyt | 2026-Q3 | 99.93 | 6.86 | 91.5 | Supplier-supplied | 1 | MARGINAL |
| AX-2026-041977 | TFC | TFC-2605-U5564 | Medutest | 2026-Q3 | 99.19 | 6.76 | 103.8 | Supplier-supplied | 1 | MARGINAL |
| AX-2026-041972 | TFC | TFC-2605-U5564 | Janoshik | 2026-Q3 | 99.48 | 6.11 | 92.0 | Supplier-supplied | 1 | MARGINAL |
| AX-2026-041974 | TFC | TFC-2605-U5564 | Janoshik | 2026-Q3 | 99.93 | 6.31 | 96.6 | Supplier-supplied | 1 | MARGINAL |
| Report | Compound | Lot | Lab | Quarter | Purity % | Water % | Recovery % | Provenance | Flags | Result |
|---|---|---|---|---|---|---|---|---|---|---|
| AX-2026-041453 | Retatrutide | QYB-2604-B5660 | VendorInvestigate | 2026-Q3 | 98.02 | 2.55 | — | Buyer-sourced | 1 | MARGINAL |
| AX-2026-041454 | Retatrutide | QYB-2604-B5660 | Janoshik | 2026-Q3 | 98.84 | 2.77 | — | Supplier-supplied | 1 | MARGINAL |
| AX-2026-041538 | Retatrutide | QYB-2602-G6308 | Medutest | 2026-Q3 | 98.50 | 2.85 | — | Supplier-supplied | 2 | MARGINAL |
| AX-2026-041456 | Retatrutide | QYB-2604-B5660 | Janoshik | 2026-Q3 | 98.23 | 3.24 | — | Supplier-supplied | 1 | MARGINAL |
| AX-2026-041452 | Retatrutide | QYB-2604-B5660 | Nordanalyt | 2026-Q3 | 98.50 | 3.36 | — | Supplier-supplied | 1 | MARGINAL |
| AX-2026-041427 | Ipamorelin | QYB-2605-H4298 | Janoshik | 2026-Q3 | 99.93 | 4.12 | — | Supplier-supplied | 0 | PASS |
| AX-2026-041488 | PT-141 (Bremelanotide) | QYB-2607-L5615 | Janoshik | 2026-Q3 | 99.93 | 3.79 | — | Supplier-supplied | 0 | PASS |
| AX-2026-041459 | Retatrutide | QYB-2604-B5660 | VendorInvestigate | 2026-Q3 | 97.91 | 2.84 | 92.2 | Buyer-sourced | 1 | MARGINAL |